What is the typical dose of topical testosterone (TT) used to treat low libido in postmenopausal women?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Topical Testosterone Dosing for Postmenopausal Women

The typical dose of topical testosterone for treating low libido in postmenopausal women is 10 mg daily, applied as a cream or gel to the skin. 1, 2

Evidence-Based Dosing Recommendations

Standard Dosing Protocol

  • 10 mg daily of testosterone cream or gel is the most commonly studied and effective dose for improving sexual desire and function in postmenopausal women with hypoactive sexual desire disorder 1, 2, 3

  • The 10 mg dose consistently raises serum testosterone levels into the mid- to high-normal premenopausal range (approximately 3.2 nmol/L) without causing supraphysiologic levels 2

  • Application involves spreading the gel or cream over approximately 15 cm² of skin, typically on the outer thigh, once daily in the morning 2

Dose-Response Data

  • A pharmacokinetic study in postmenopausal women tested 4.4 mg, 8.8 mg, and 13.2 mg doses, finding that 4.4 mg raised testosterone to mid-to-high normal range, while higher doses (8.8-13.2 mg) produced supraphysiologic levels 4

  • Another study comparing 10 mg, 20 mg, and 30 mg doses found adequate serum levels achieved with 10 mg, with diminishing returns at higher doses (20 mg produced 7.2 nmol/L vs 7.5 nmol/L at 30 mg) 2

  • The 10 mg dose represents the optimal balance between efficacy and safety, avoiding unnecessarily elevated testosterone levels 1, 2

Clinical Efficacy at 10 mg Dose

  • In a randomized, placebo-controlled trial, 10 mg daily testosterone cream significantly improved sexual desire, frequency of sexual activity, receptivity, and initiation in postmenopausal hysterectomized women already on estrogen therapy 1

  • The same dose improved psychological well-being, mood, and sexual function scores in premenopausal women with low libido, suggesting efficacy across reproductive stages 3

  • Treatment effects become apparent within 3 months and are sustained with continued use 1

Application Technique

  • Apply once daily, preferably in the morning at the same time each day 2

  • Spread thinly over approximately 15 cm² of skin on the outer thigh 2

  • Allow to dry completely before dressing to minimize transfer risk 4

  • Steady-state testosterone levels are achieved within 3-5 days of daily application 2

Monitoring Considerations

  • Baseline total and free testosterone levels should be measured before initiating therapy 1, 3

  • Testosterone levels should be checked 2-3 months after starting treatment to ensure levels are in the mid-to-high normal premenopausal range 2, 4

  • The 10 mg dose does not significantly affect estradiol, LH, FSH, or SHBG levels 4

  • Concomitant estrogen therapy does not alter testosterone pharmacokinetics, so dose adjustments are not needed based on estrogen use 4

Safety Profile at Recommended Dose

  • The 10 mg daily dose has demonstrated no significant adverse effects over 3-month treatment periods 1

  • No changes in lipids, blood pressure, or weight were observed at this dose 1

  • The formulation is well-tolerated with minimal skin reactions when applied as a gel rather than patch 1, 2

Context from Guidelines

While the provided guidelines primarily address estrogen replacement and focus on cancer survivors or premature ovarian insufficiency 5, they do acknowledge that intravaginal testosterone cream has been studied in postmenopausal breast cancer survivors on aromatase inhibitors and was found safe for improving vaginal atrophy and sexual function 5. However, these guidelines do not specify systemic dosing for libido, making the research evidence the primary source for this indication.

Important caveat: The evidence for topical testosterone in postmenopausal women with low libido is based on relatively short-term studies (3-6 months). Long-term safety data beyond this timeframe are limited, though no concerning signals emerged in available trials 1, 2, 3, 4.

References

Research

Percutaneous administration of testosterone gel in postmenopausal women--a pharmacological study.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2005

Research

Pharmacokinetics of a testosterone gel in healthy postmenopausal women.

The Journal of clinical endocrinology and metabolism, 2006

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.